Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Gentilcore, Giusy ^a   Madonna, Gabriele ^a   Mozzillo, Nicola ^a   Ribas, Antoni ^b   Cossu, Antonio ^c   Palmieri, Giuseppe ^d   Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^d CNR   (Italy)

Author keywords

BRAF inhibitor; Dabrafenib; Growth inhibition; Melanoma therapy

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; BRAF GENE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA CELL;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMIDAZOLES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84872122524     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-17     Document Type: Article

References (9)

1. Nissan MH, Solit DB. The " SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?. Curr Oncol Rep 2011, 13:479-487. 10.1007/s11912-011-0198-4, 21997758.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
3. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin Cancer Res 2012, 18:3242-3249. 10.1158/1078-0432.CCR-12-0052, 22535154.
4. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini MC, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012, 30:2522-2529. 10.1200/JCO.2011.41.2452, 22614978.
5. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70:5518-5527. 10.1158/0008-5472.CAN-10-0646, 20551065.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, . BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808, BRIM-3 Study Group.
7. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2012, 25:248-258. 10.1111/j.1755-148X.2011.00950.x, 22171948.
8. Trefzer UD, Minor D, Ribas A, Lebbe C, Siegfried A, Arya N, Guckert M, Schadendorf D, Kefford R, Grob JJ, Hamid O, Amaravadi R, Simeone E, TWilhelm T, Kim K, Goodman V, Ascierto PA. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2 118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Res 2011, 24:1020. abstract LBA1-1.
9. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901. 10.1016/S0140-6736(12)60398-5, 22608338.